Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of “Moderate Buy” from Analysts

Certara, Inc. (NASDAQ:CERT) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $15.17.

A number of equities analysts have recently issued reports on CERT shares. Robert W. Baird increased their target price on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. William Blair reissued a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 price target on the stock. Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays decreased their price objective on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th.

Certara Trading Up 1.2 %

NASDAQ CERT opened at $14.42 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $2.33 billion, a P/E ratio of -72.10, a P/E/G ratio of 9.29 and a beta of 1.64. Certara has a 52-week low of $8.64 and a 52-week high of $17.94. The firm has a 50-day moving average price of $11.65 and a 200 day moving average price of $11.55.

Hedge Funds Weigh In On Certara

Several hedge funds have recently added to or reduced their stakes in CERT. Versant Capital Management Inc lifted its holdings in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in Certara in the 4th quarter valued at approximately $47,000. Finally, Blue Trust Inc. grew its holdings in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after buying an additional 822 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.